Artigos de revistas: "Interleukin-6"

1

&NA;. "Interleukin-3/interleukin-6". Reactions Weekly &NA;, n.º 550 (maio de 1995): 11. http://dx.doi.org/10.2165/00128415-199505500-00035.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

2

&NA;. "Interleukin-6". Reactions Weekly &NA;, n.º 570 (setembro de 1995): 9. http://dx.doi.org/10.2165/00128415-199505700-00023.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

3

Lotz, Martin. "Interleukin-6". Cancer Investigation 11, n.º 6 (janeiro de 1993): 732–42. http://dx.doi.org/10.3109/07357909309046948.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

4

&NA;. "Interleukin 6". Inpharma Weekly &NA;, n.º 877 (março de 1993): 2. http://dx.doi.org/10.2165/00128413-199308770-00001.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

5

&NA;. "Interleukin 6". Reactions Weekly &NA;, n.º 505 (junho de 1994): 8. http://dx.doi.org/10.2165/00128415-199405050-00037.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

6

&NA;. "Interleukin 6". Reactions Weekly &NA;, n.º 531 (dezembro de 1994): 8. http://dx.doi.org/10.2165/00128415-199405310-00027.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

7

Song, Mingchen, e John A. Kellum. "Interleukin-6". Critical Care Medicine 33, Suppl (dezembro de 2005): S463—S465. http://dx.doi.org/10.1097/01.ccm.0000186784.62662.a1.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

8

CASTELL, JOSé V., TILO ANDUS, DIETER KUNZ e PETER C. HEINRICH. "Interleukin-6". Annals of the New York Academy of Sciences 557, n.º 1 (28 de junho de 2008): 87–101. http://dx.doi.org/10.1111/j.1749-6632.1989.tb24001.x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

9

LEE, FRANK, CHOY-PIK CHIU, JANUSZ WIDEMAN, PHILLIP HODGKIN, SUSAN HUDAK, LOUISE TROUTT, THERESA NG et al. "Interleukin-6". Annals of the New York Academy of Sciences 557, n.º 1 (28 de junho de 2008): 215–29. http://dx.doi.org/10.1111/j.1749-6632.1989.tb24015.x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

10

CLARK, STEVEN C. "Interleukin-6". Annals of the New York Academy of Sciences 557, n.º 1 (28 de junho de 2008): 438–43. http://dx.doi.org/10.1111/j.1749-6632.1989.tb24036.x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

11

Olencki, Thomas, James Finke e Ronald M. Bukowski. "Interleukin-6". Clinical Immunotherapeutics 2, n.º 4 (outubro de 1994): 278–94. http://dx.doi.org/10.1007/bf03258528.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

12

Sin, Don D., e S. F. Paul Man. "Interleukin-6". Chest 133, n.º 1 (janeiro de 2008): 4–6. http://dx.doi.org/10.1378/chest.07-2085.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

13

Delk, Nikki A., e Mary C. Farach-Carson. "Interleukin-6". Autophagy 8, n.º 4 (abril de 2012): 650–63. http://dx.doi.org/10.4161/auto.19226.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

14

Matsuda, Tadashi, e Toshio Hirano. "Interleukin 6 (IL-6)". Biotherapy 2, n.º 4 (outubro de 1990): 363–73. http://dx.doi.org/10.1007/bf02170085.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

15

Rivera-Chavez, Fernando A., Dixie L. Peters-Hybki, Robert C. Barber e Grant E. O'Keefe. "Interleukin-6 Promoter Haplotypes and Interleukin-6 Cytokine Responses". Shock 20, n.º 3 (setembro de 2003): 218–23. http://dx.doi.org/10.1097/00024382-200309000-00004.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

16

Ridker, Paul M. "Targeting Interleukin-1 and Interleukin-6". Journal of the American College of Cardiology 76, n.º 15 (outubro de 2020): 1774–76. http://dx.doi.org/10.1016/j.jacc.2020.08.052.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

17

NORTHEMANN, WOLFGANG, TODD A. BFUCIAK, MASAHIRA HATTORI e GEORG H. FEY. "Rat Interleukin-6". Annals of the New York Academy of Sciences 557, n.º 1 (28 de junho de 2008): 536–39. http://dx.doi.org/10.1111/j.1749-6632.1989.tb24057.x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

18

Schneider, Kirsten, Reinhard Klaas, Bernd Kaspers e Peter Staeheli. "Chicken interleukin-6". European Journal of Biochemistry 268, n.º 15 (1 de agosto de 2001): 4200–4206. http://dx.doi.org/10.1046/j.1432-1327.2001.02334.x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

19

Tamura, T., N. Udagawa, N. Takahashi, C. Miyaura, S. Tanaka, Y. Yamada, Y. Koishihara, Y. Ohsugi, K. Kumaki e T. Taga. "Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6." Proceedings of the National Academy of Sciences 90, n.º 24 (15 de dezembro de 1993): 11924–28. http://dx.doi.org/10.1073/pnas.90.24.11924.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

20

Ogawa, Michio, Kiyoshi Sakamoto, Seiji Mita, Takatoshi Ishiko e Saburo Hisano. "INTERLEUKIN-6 AND SOLUBLE INTERLEUKIN-6 RECEPTOR IN SURGICAL TRAUMA". Shock 4, Supplement (dezembro de 1995): 11. http://dx.doi.org/10.1097/00024382-199512001-00045.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

21

De Filippo, G., D. Rendina, F. Moccia, V. Rocco e A. Campanozzi. "Interleukin-6, soluble interleukin-6 receptor/interleukin-6 complex and insulin resistance in obese children and adolescents". Journal of Endocrinological Investigation 38, n.º 3 (23 de setembro de 2014): 339–43. http://dx.doi.org/10.1007/s40618-014-0176-4.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

22

Oka, Masaaki, Hiroshi Kusanagi, Toshihiro Saeki, Norio Iizuka, Hiroto Hayashi, Akira Tangoku, Takuo Murakami e Takashi Suzuki. "Interleukin-6 Production and Interleukin-6 Receptor Expression in Human Esophageal Cancer Cell Lines". Japanese Journal of Gastroenterological Surgery 26, n.º 11 (1993): 2707. http://dx.doi.org/10.5833/jjgs.26.2707.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

23

Prens, Errol P., Klazina Benne, Jozef van Damme, Marleen Bakkus, Karin Brakel, Robbert Benner e Theodoor van Joost. "Interleukin-1 and Interleukin-6 in Psoriasis". Journal of Investigative Dermatology 95, n.º 6 (dezembro de 1990): S121—S124. http://dx.doi.org/10.1111/1523-1747.ep12874991.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

24

Bota, Rafaqat, e Mushtaq Ahmed. "The pathophysiological profile of interleukin-6 and anti-interleukin-6 antibody". El Mednifico Journal 1, n.º 2 (6 de julho de 2013): 51. http://dx.doi.org/10.18035/emj.v1i2.26.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

25

Ridker, Paul M., e Manas Rane. "Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease". Circulation Research 128, n.º 11 (28 de maio de 2021): 1728–46. http://dx.doi.org/10.1161/circresaha.121.319077.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

Resumo:

IL (interleukin)-6 is a pivotal cytokine of innate immunity, which enacts a broad set of physiological functions traditionally associated with host defense, immune cell regulation, proliferation, and differentiation. Following recognition of innate immune pathways leading from the NLRP3 (NOD-, LRR-, and pyrin domain-containing protein 3) inflammasome to IL-1 to IL-6 and on to the hepatically derived clinical biomarker CRP (C-reactive protein), an expanding literature has led to understanding of the proatherogenic role for IL-6 in cardiovascular disease and thus the potential for IL-6 inhibition as a novel method for vascular protection. In this review, we provide an overview of the mechanisms by which IL-6 signaling occurs and how that impacts upon pharmacological inhibition; describe murine models of IL-6 and atherogenesis; summarize human epidemiological data outlining the utility of IL-6 as a biomarker of vascular risk; outline genetic data suggesting a causal role for IL-6 in systemic atherothrombosis and aneurysm formation; and then detail the potential role of IL-6 inhibition in stable coronary disease, acute coronary syndromes, heart failure, and the atherothrombotic complications associated with chronic kidney disease and end-stage renal failure. Finally, we review anti-inflammatory and antithrombotic findings for ziltivekimab, a novel IL-6 ligand inhibitor being developed specifically for use in atherosclerotic disease and poised to be tested formally in a large-scale cardiovascular outcomes trial focused on individuals with chronic kidney disease and elevated levels of CRP, a population at high residual atherothrombotic risk, high residual inflammatory risk, and considerable unmet clinical need.

26

Jucker, M., H. Abts, W. Li, R. Schindler, H. Merz, A. Gunther, C. von Kalle, M. Schaadt, T. Diamantstein e AC Feller. "Expression of interleukin-6 and interleukin-6 receptor in Hodgkin's disease". Blood 77, n.º 11 (1 de junho de 1991): 2413–18. http://dx.doi.org/10.1182/blood.v77.11.2413.2413.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

Resumo:

Abstract Interleukin-6 (IL-6) is a multipotent lymphokine that can mediate differentiation of B cells into Ig-secreting cells, stimulate the growth of plasmacytomas, hybridomas, and T cells, and induce acute- phase proteins in liver cells. It has been suggested that IL-6 is involved in the pathogenesis of several diseases by autocrine or paracrine pathways. To examine whether IL-6 is possibly involved in the pathophysiology of Hodgkin's disease (HD), we analyzed the expression of IL-6 and IL-6 receptor mRNA and protein in cell lines and primary specimens from patients with HD. IL-6-specific transcripts were detected in three of six HD-derived cell lines by Northern blot analysis. In the culture supernatants of four HD-derived cell lines, IL- 6 was detected by radioimmunoassay. Biologic activity of IL-6 was confirmed by proliferation of an IL-6-dependent cell line. In situ hybridization experiments showed IL-6-specific transcripts in Hodgkin (H) and Reed-Sternberg (RS) cells in primary tissues of two patients. In addition, mRNAs specific for the IL-6 receptor were detected in five HD-derived cell lines. Immunostaining experiments showed expression of IL-6 receptor molecules on H and RS cells in 8 of 16 cases with HD. Thus, our data suggest that IL-6 might be involved in the pathophysiology of HD.

27

Jucker, M., H. Abts, W. Li, R. Schindler, H. Merz, A. Gunther, C. von Kalle, M. Schaadt, T. Diamantstein e AC Feller. "Expression of interleukin-6 and interleukin-6 receptor in Hodgkin's disease". Blood 77, n.º 11 (1 de junho de 1991): 2413–18. http://dx.doi.org/10.1182/blood.v77.11.2413.bloodjournal77112413.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

Resumo:

Interleukin-6 (IL-6) is a multipotent lymphokine that can mediate differentiation of B cells into Ig-secreting cells, stimulate the growth of plasmacytomas, hybridomas, and T cells, and induce acute- phase proteins in liver cells. It has been suggested that IL-6 is involved in the pathogenesis of several diseases by autocrine or paracrine pathways. To examine whether IL-6 is possibly involved in the pathophysiology of Hodgkin's disease (HD), we analyzed the expression of IL-6 and IL-6 receptor mRNA and protein in cell lines and primary specimens from patients with HD. IL-6-specific transcripts were detected in three of six HD-derived cell lines by Northern blot analysis. In the culture supernatants of four HD-derived cell lines, IL- 6 was detected by radioimmunoassay. Biologic activity of IL-6 was confirmed by proliferation of an IL-6-dependent cell line. In situ hybridization experiments showed IL-6-specific transcripts in Hodgkin (H) and Reed-Sternberg (RS) cells in primary tissues of two patients. In addition, mRNAs specific for the IL-6 receptor were detected in five HD-derived cell lines. Immunostaining experiments showed expression of IL-6 receptor molecules on H and RS cells in 8 of 16 cases with HD. Thus, our data suggest that IL-6 might be involved in the pathophysiology of HD.

28

Plenz, Gabriele, Heike Eschert, Michael Erren, Thomas Wichter, Michael Böhm, Markus Flesch, Hans H. Scheld e Mario C. Deng. "The interleukin-6/interleukin-6-receptorsystem is activated in donor hearts". Journal of the American College of Cardiology 39, n.º 9 (maio de 2002): 1508–12. http://dx.doi.org/10.1016/s0735-1097(02)01791-6.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

29

Nancey, Stéphane, Nadim Hamzaoui, Driffa Moussata, Ivan Graber, Jacques Bienvenu e Bernard Flourie. "Serum Interleukin-6, Soluble Interleukin-6 Receptor and Crohn’s Disease Activity". Digestive Diseases and Sciences 53, n.º 1 (5 de junho de 2007): 242–47. http://dx.doi.org/10.1007/s10620-007-9849-6.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

30

Angelis, Pela, Simon Scharf, Alastair Mander, Frank Vajda e Nicholas Christophidis. "Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease". Neuroscience Letters 244, n.º 2 (março de 1998): 106–8. http://dx.doi.org/10.1016/s0304-3940(98)00136-0.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

31

Rezai, Ali R., Ahmad Rezai, Otoniel Mart�nez-Maza, Meta Vander-Meyden e Martin H. Weiss. "Interleukin-6 and interleukin-6 receptor gene expression in pituitary tumors". Journal of Neuro-Oncology 19, n.º 2 (junho de 1994): 131–35. http://dx.doi.org/10.1007/bf01306454.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

32

MONTERO-JULIAN, F. A., E. GAUTHEROT, J. WIJDENES, B. KLEIN e H. BRAILLY. "Pharmacokinetics of Interleukin-6 During Therapy with Anti-Interleukin-6 Monoclonal Antibodies: Enhanced Clearance of Interleukin-6 by a Combination of Three Anti-Interleukin-6 Antibodies". Journal of Interferon Research 14, n.º 5 (outubro de 1994): 301–2. http://dx.doi.org/10.1089/jir.1994.14.301.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

33

KENIS, G., C. TEUNISSEN, R. DEJONGH, E. BOSMANS, H. STEINBUSCH e M. MAES. "STABILITY OF INTERLEUKIN 6, SOLUBLE INTERLEUKIN 6 RECEPTOR, INTERLEUKIN 10 AND CC16 IN HUMAN SERUM". Cytokine 19, n.º 5 (setembro de 2002): 228–35. http://dx.doi.org/10.1016/s1043-4666(02)91961-7.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

34

Kenis, Gunter, Charlotte Teunissen, Raf De Jongh, Eugène Bosmans, Harry Steinbusch e Michael Maes. "STABILITY OF INTERLEUKIN 6, SOLUBLE INTERLEUKIN 6 RECEPTOR, INTERLEUKIN 10 AND CC16 IN HUMAN SERUM". Cytokine 19, n.º 5 (setembro de 2002): 228–35. http://dx.doi.org/10.1006/cyto.2002.1961.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

35

HIRANO, TOSHIO. "Interleukin 6 (IL-6) and disease." Japanese Journal of Clinical Immunology 13, n.º 5 (1990): 444–45. http://dx.doi.org/10.2177/jsci.13.444.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

36

Van Wagoner, N. J., e E. N. Benveniste. "Interleukin-6 regulation in human astrocytes: Synergy between TNF-alpha, interleukin-6, and the soluble-interleukin-6 receptor-alpha". Journal of Neuroimmunology 90, n.º 1 (setembro de 1998): 53. http://dx.doi.org/10.1016/s0165-5728(98)91497-7.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

37

Hoejberg, Lise, Lars Bastholt e Henrik Schmidt. "Interleukin-6 and melanoma". Melanoma Research 22, n.º 5 (outubro de 2012): 327–33. http://dx.doi.org/10.1097/cmr.0b013e3283543d72.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

38

Rose-John, Stefan. "Interleukin-6 Family Cytokines". Cold Spring Harbor Perspectives in Biology 10, n.º 2 (15 de junho de 2017): a028415. http://dx.doi.org/10.1101/cshperspect.a028415.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

39

Tanaka, Toshio, Masashi Narazaki e Tadamitsu Kishimoto. "Interleukin (IL-6) Immunotherapy". Cold Spring Harbor Perspectives in Biology 10, n.º 8 (4 de agosto de 2017): a028456. http://dx.doi.org/10.1101/cshperspect.a028456.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

40

Suzuki, Kenshi, Akiko Miyashita, Yasuyuki Inoue, Seiko Iki, Hidetoshi Enomoto, Yuji Takahashi e Tamiko Takemura. "Interleukin-6-Producing Pheochromocytoma". Acta Haematologica 85, n.º 4 (1991): 217–19. http://dx.doi.org/10.1159/000204897.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

41

Kerr, Ron, David Stirling e Christopher A. Ludlam. "Interleukin 6 and Haemostasis". British Journal of Haematology 115, n.º 1 (outubro de 2001): 3–12. http://dx.doi.org/10.1046/j.1365-2141.2001.03061.x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

42

Sehgal, Pravinkumar B. "Interleukin-6: Molecular Pathophysiology". Journal of Investigative Dermatology 94, n.º 6 (junho de 1990): s2—s6. http://dx.doi.org/10.1111/1523-1747.ep12874963.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

43

Van Snick, Jacques. "Interleukin-6: An Overview". Annual Review of Immunology 8, n.º 1 (abril de 1990): 253–78. http://dx.doi.org/10.1146/annurev.iy.08.040190.001345.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

44

Pedersen, Bente Klarlund, Adam Steensberg e Peter Schjerling. "Exercise and interleukin-6". Current Opinion in Hematology 8, n.º 3 (maio de 2001): 137–41. http://dx.doi.org/10.1097/00062752-200105000-00002.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

45

Patarca, Roberto, e Mary Ann Fletcher. "Interleukin-6 and Disease". Journal of Chronic Fatigue Syndrome 4, n.º 1 (janeiro de 1998): 53–69. http://dx.doi.org/10.1300/j092v04n01_07.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

46

SEHGAL, PRAVIN B., LING WANG, RAVI RAYANADE, HENG PAN e LOLA MARGULIES. "Interleukin-6-Type Cytokinesa". Annals of the New York Academy of Sciences 762, n.º 1 (17 de dezembro de 2006): 1–14. http://dx.doi.org/10.1111/j.1749-6632.1995.tb32309.x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

47

Mehra, Reena. "Soluble Interleukin 6 Receptor". Archives of Internal Medicine 166, n.º 16 (18 de setembro de 2006): 1725. http://dx.doi.org/10.1001/archinte.166.16.1725.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

48

Henkin, Robert I., Loren Schmidt e Irina Velicu. "Interleukin 6 in Hyposmia". JAMA Otolaryngology–Head & Neck Surgery 139, n.º 7 (1 de julho de 2013): 728. http://dx.doi.org/10.1001/jamaoto.2013.3392.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

49

Tesch, H., M. Jüjcler, S. Klein, H. Abts, A. Güjnther, G. R. F. Krueger e V. Diehl. "Hodgkin and Reed-Sternberg Cells Express Interleukin 6 and Interleukin 6 Receptors". Leukemia & Lymphoma 7, n.º 4 (janeiro de 1992): 297–303. http://dx.doi.org/10.3109/10428199209049781.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

50

Peters, Malte, Guido Blinn, Thomas Jostock, Peter Schirmacher, Karl–Hermann Meyer Zum Büschenfelde, Peter R. Galle e Stefan Rose–John. "Combined interleukin 6 and soluble interleukin 6 receptor accelerates murine liver regeneration". Gastroenterology 119, n.º 6 (dezembro de 2000): 1663–71. http://dx.doi.org/10.1053/gast.2000.20236.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

Artigos de revistas sobre o tema "Interleukin-6"

Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos